News on immunoassay systems and applications.
Company executives highlighted recent and upcoming product launches expected to drive growth in its molecular, microbiology, and immunoassay businesses.
BioMérieux Q4 Revenues up 11 Percent
The firm saw growth across all its businesses in the fourth quarter, while full-year revenues were flat compared to 2021.
Lucira Health won't be the last COVID-19-focused firm to face bankruptcy, layoffs, or stock price declines, as "COVID cash" dries up, experts said.
For the fourth quarter ended Dec. 31, QuidelOrtho reported revenues of $866.5 million, up 36 percent from $636.9 million in the year-ago quarter and in line with previously reported preliminary revenues.
Adaptive Biotechnologies Lays out Strategy to Drive ClonoSeq Adoption
The Seattle-based immune sequencing firm reported a 46 percent increase in fourth quarter revenues, about equally split between its MRD and immune medicine businesses.